COVID-19

HyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchHyBryte™ Treatment Studies Presented at Two Medical Conferences in March

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6,…

2 months ago
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment…

2 months ago
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible DebentureHemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous…

2 months ago
Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight PartnersMedical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners

Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners

NEW YORK, March 4, 2025 /PRNewswire/ -- According to a comprehensive report from The Insight Partners, "Medical Refrigerators Market Size and…

2 months ago
MyClearStep and Teamworks Shake Up Athlete Performance Tech–A Seamless Integration That’s Changing the GameMyClearStep and Teamworks Shake Up Athlete Performance Tech–A Seamless Integration That’s Changing the Game

MyClearStep and Teamworks Shake Up Athlete Performance Tech–A Seamless Integration That’s Changing the Game

CUPERTINO, Calif., March 4, 2025 /PRNewswire/ -- Say goodbye to outdated weigh-ins and hello to precision, efficiency, and next-level insights. MyClearStep,…

2 months ago
VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight ManagementVIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management

VIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight Management

VIVUS reaffirms commitment to combatting global obesity crisis on World Obesity Day 2025 with VIVUS For Life CAMPBELL, Calif., March…

2 months ago
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to PreventionColorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) --  Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

2 months ago
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory BoardOryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality…

2 months ago
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingInflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…

2 months ago
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the…

2 months ago
Show more Posts
Show previous Posts